Literature DB >> 10856700

A large "footprint" at the boundary of the human beta-globin locus control region hypersensitive site-2.

A Kim1, V Murray.   

Abstract

The 5'-boundary region of the human beta-globin locus control region hypersensitive site-2 (HS-2) was examined for protein-DNA interactions. The HS-2 is an erythroid specific DNase I hypersensitive site that extends for approximately 600 bp. Erythroid K562 cells and non-erythroid HeLa cells were damaged by bleomycin and hedamycin--these agents are able to "footprint" nucleosome cores and proteins bound to DNA. The fragments generated by DNA damage were amplified by the ligation-mediated polymerase chain reaction with primers specific for the 5'-boundary region of HS-2 and examined at base pair resolution on DNA sequencing gels. The intensity of damage in intact cells was compared with that in purified DNA. The comparison between intact cells and purified DNA revealed a protected region of 226 bp with bleomycin and 182 bp with hedamycin in K562 cells. The length of the protected region was consistent with the presence of a nucleosome core. We postulate that an erythroid-specific protein binds next to the positioned nucleosome at the boundary of HS-2 to prevent sliding of the nucleosome into the hypersensitive site--this would also account for the large size of the protected region. HeLa cells (lacking a hypersensitive site in the beta-globin cluster) did not have an area of protection in this region.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10856700     DOI: 10.1016/s1357-2725(00)00023-6

Source DB:  PubMed          Journal:  Int J Biochem Cell Biol        ISSN: 1357-2725            Impact factor:   5.085


  8 in total

1.  The DNA sequence specificity of bleomycin cleavage in a systematically altered DNA sequence.

Authors:  Shweta D Gautam; Jon K Chen; Vincent Murray
Journal:  J Biol Inorg Chem       Date:  2017-05-16       Impact factor: 3.358

2.  Zorbamycin has a different DNA sequence selectivity compared with bleomycin and analogues.

Authors:  Jon K Chen; Dong Yang; Ben Shen; Brett A Neilan; Vincent Murray
Journal:  Bioorg Med Chem       Date:  2016-09-30       Impact factor: 3.641

3.  Human telomeric DNA sequences are a major target for the antitumour drug bleomycin.

Authors:  Trung V Nguyen; Vincent Murray
Journal:  J Biol Inorg Chem       Date:  2011-07-15       Impact factor: 3.358

4.  The DNA sequence specificity of bleomycin cleavage in telomeric sequences in human cells.

Authors:  Hanh T Q Nguyen; Vincent Murray
Journal:  J Biol Inorg Chem       Date:  2012-09-09       Impact factor: 3.358

5.  The genome-wide DNA sequence specificity of the anti-tumour drug bleomycin in human cells.

Authors:  Vincent Murray; Jon K Chen; Mark M Tanaka
Journal:  Mol Biol Rep       Date:  2016-05-17       Impact factor: 2.316

6.  The anti-tumor drug bleomycin preferentially cleaves at the transcription start sites of actively transcribed genes in human cells.

Authors:  Vincent Murray; Jon K Chen; Anne M Galea
Journal:  Cell Mol Life Sci       Date:  2013-08-28       Impact factor: 9.261

7.  The determination of the DNA sequence specificity of bleomycin-induced abasic sites.

Authors:  Jon K Chen; Vincent Murray
Journal:  J Biol Inorg Chem       Date:  2016-03-03       Impact factor: 3.358

Review 8.  The Interaction of the Metallo-Glycopeptide Anti-Tumour Drug Bleomycin with DNA.

Authors:  Vincent Murray; Jon K Chen; Long H Chung
Journal:  Int J Mol Sci       Date:  2018-05-04       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.